Key terms

About DHR

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest DHR news

Nov 15 10:15am ET Danaher put volume heavy and directionally bearish Nov 14 4:36pm ET Third Point exits Alphabet, cuts stakes in Microsoft, Amazon, Meta, Apple Oct 31 9:45am ET Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls Oct 31 5:20am ET Danaher upgraded to Outperform from Peer Perform at Wolfe Research Oct 24 10:35am ET Danaher’s Resilience and Long-Term Potential Justifies Buy Rating Despite Short-Term Challenges Oct 23 10:05am ET Danaher price target lowered to $311 from $333 at RBC Capital Oct 23 9:16am ET Danaher price target lowered to $300 from $310 at Raymond James Oct 23 8:41am ET Danaher price target raised to $265 from $250 at Stifel Oct 23 8:06am ET Jefferies Reaffirms Their Buy Rating on Danaher (DHR) Oct 23 7:36am ET Danaher price target raised to $315 from $310 at TD Cowen Oct 23 7:36am ET Stifel Nicolaus Keeps Their Hold Rating on Danaher (DHR) Oct 23 7:06am ET Danaher price target raised to $310 from $290 at KeyBanc Oct 23 6:57am ET RBC Capital Reaffirms Their Buy Rating on Danaher (DHR) Oct 23 6:47am ET Cautious Outlook for Danaher: Hold Rating Amidst Bioprocessing Recovery and Life Sciences Challenges Oct 23 6:30am ET Danaher price target lowered to $277 from $278 at Baird Oct 23 5:17am ET Cautious Outlook for Danaher: Hold Rating Maintained Amid 2025 Uncertainties Oct 23 4:50am ET Danaher price target lowered to $275 from $285 at Barclays Oct 23 3:17am ET Danaher (DHR) Gets a Hold from Barclays Oct 22 7:55pm ET Optimistic Outlook for Danaher Despite Short-Term Challenges in Bioprocessing Sector Oct 22 5:40pm ET Danaher price target raised to $255 from $250 at Goldman Sachs Oct 22 8:55am ET Morning Movers: 3M gains and GE Aerospace falls following third quarter results Oct 22 6:12am ET Danaher backs FY24 revenue view down low-single digits Oct 22 6:05am ET Danaher reports Q3 adjusted EPS $1.71, consensus $1.57 Oct 22 6:05am ET Danaher sees Q4 revenue down low-single digits Oct 21 2:23pm ET Notable companies reporting before tomorrow’s open Oct 15 9:53pm ET Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Thermo Fisher (TMO) Oct 15 9:49pm ET RBC Capital Sticks to Their Buy Rating for Danaher (DHR) Oct 07 9:10am ET Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Genenta Science SpA Sponsored ADR (GNTA) Oct 01 8:47am ET Danaher price target raised to $278 from $275 at Evercore ISI Sep 30 4:20pm ET Danaher initiated with an Overweight at Stephens Sep 25 9:48pm ET RBC Capital Sticks to Its Buy Rating for Danaher (DHR)

DHR Financials

1-year income & revenue

Key terms

DHR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

DHR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms